Roble, Belko & Company, Inc Eli Lilly & CO Transaction History
Roble, Belko & Company, Inc
- $687 Million
- Q2 2025
A detailed history of Roble, Belko & Company, Inc transactions in Eli Lilly & CO stock. As of the latest transaction made, Roble, Belko & Company, Inc holds 2 shares of LLY stock, worth $1,251. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2Holding current value
$1,251% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding LLY
# of Institutions
4,400Shares Held
756MCall Options Held
9.9MPut Options Held
10.9M-
Lilly Endowment Inc Indianapolis, IN96MShares$60.1 Billion0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA79.2MShares$49.6 Billion1.22% of portfolio
-
Black Rock Inc. New York, NY65.9MShares$41.2 Billion1.37% of portfolio
-
Pnc Financial Services Group, Inc. Pittsburgh, PA51.3MShares$32.1 Billion26.07% of portfolio
-
State Street Corp Boston, MA34.4MShares$21.5 Billion1.2% of portfolio
About ELI LILLY & Co
- Ticker LLY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 950,174,976
- Market Cap $594B
- Description
- Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...